Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Archives of Gynecology and Obstetrics
Published in: Archives of Gynecology and Obstetrics 6/2018

01-06-2018 | Gynecologic Oncology

miR-101-3p induces autophagy in endometrial carcinoma cells by targeting EZH2

Authors: Cuilan Wang, Bo Liu

Published in: Archives of Gynecology and Obstetrics | Issue 6/2018

Login to get access

Abstract

Objective

This study aimed to investigate the effect of miR-101-3p on autophagy in endometrial carcinoma (EC) cells and the connection between miR-101-3p and EZH2.

Methods

The expression levels of miRNAs were analyzed by microarray. The expression level of autophagy related proteins was measured by western blot. The mRNA expression level of beclin-1 was determined by qRT-PCR. Autophagy in EC cells was traced by GFP-LC3 fusion protein and observed by fluorescence microscopy. The number of autophagic vacuoles was determined by transmission electron microscopy (TEM). A luciferase reporter assay was utilized to assess the target relationship between miR-101-3p and EZH2.

Results

The expression level of miR-101-3p in EC tissues was lower than in normal tissues. miR-101-3p upregulated the expression levels of the autophagy-related proteins LC3-II and beclin-1 in EC cells in a time- and dose-dependent manner. Overexpression of miR-101-3p and silencing of EZH2 both promoted autophagy in EC cells. Luciferase reporter assays verified that miR-101-3p inhibited EZH2 expression by binding to its 3’-UTR region.

Conclusion

miR-101-3p promoted autophagy in EC cells by downregulating the expression of EZH2, and it induced autophagy in EC cells by suppressing EZH2 expression. Inhibition of miR-101-3p could reduce its autophagy induction effect on EC cells.
Literature
1.
Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E (2016) Endometrial cancer. Lancet 387:1094–1108CrossRefPubMed
2.
Eritja N, Chen BJ, Rodriguez-Barrueco R et al (2017) Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. Autophagy 13:608–624CrossRefPubMedPubMedCentral
3.
4.
Tangjitgamol S, See HT, Kavanagh J (2011) Adjuvant chemotherapy for endometrial cancer. Int J Gynecol Cancer 21:885–895CrossRefPubMed
5.
6.
Konno Y, Dong P, Xiong Y et al (2014) MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells. Oncotarget 5:6049–6062CrossRefPubMedPubMedCentral
7.
Sheng Y, Ding S, Chen K et al (2014) Functional analysis of miR-101-3p and Rap1b involved in hepatitis B virus-related hepatocellular carcinoma pathogenesis. Biochem Cell Biol 92:152–162CrossRefPubMed
8.
Wu J, Tao Y, Shang A et al (2017) Effect of the interaction between MiR-200b-3p and DNMT3A on cartilage cells of osteoarthritis patients. J Cell Mol Med 21:2308–2316CrossRefPubMedPubMedCentral
9.
Hiroki E, Suzuki F, Akahira J et al (2012) MicroRNA-34b functions as a potential tumor suppressor in endometrial serous adenocarcinoma. Int J Cancer 131:E395–E404CrossRefPubMed
10.
Hiroki E, Akahira J, Suzuki F et al (2010) Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci 101:241–249CrossRefPubMed
11.
Yoo KH, Hennighausen L (2012) EZH2 methyltransferase and H3K27 methylation in breast cancer. Int J Biol Sci 8:59–65CrossRefPubMed
12.
Huang D, Wang X, Zhuang C et al (2016) Reciprocal negative feedback loop between EZH2 and miR-101-1 contributes to miR-101 deregulation in hepatocellular carcinoma. Oncol Rep 35:1083–1090CrossRefPubMed
13.
Xu L, Beckebaum S, Iacob S et al (2014) MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. J Hepatol 60:590–598CrossRefPubMed
14.
Lei Q, Shen F, Wu J, Zhang W, Wang J, Zhang L (2014) MiR-101, downregulated in retinoblastoma, functions as a tumor suppressor in human retinoblastoma cells by targeting EZH2. Oncol Rep 32:261–269CrossRefPubMed
15.
Lin C, Huang F, Li QZ, Zhang YJ (2014) miR-101 suppresses tumor proliferation and migration, and induces apoptosis by targeting EZH2 in esophageal cancer cells. Int J Clin Exp Pathol 7:6543–6550PubMedPubMedCentral
16.
Luo C, Merz PR, Chen Y et al (2013) MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2. Cancer Lett 341:240–247CrossRefPubMed
17.
Peng Z, Zhang Y (2017) Methyl jasmonate induces the apoptosis of human colorectal cancer cells via downregulation of EZH2 expression by microRNA101. Mol Med Rep 15:957–962CrossRefPubMed
18.
Zhang K, Zhang Y, Ren K, Zhao G, Yan K, Ma B (2014) MicroRNA-101 inhibits the metastasis of osteosarcoma cells by downregulation of EZH2 expression. Oncol Rep 32:2143–2149CrossRefPubMed
19.
Liu L, Guo J, Yu L et al (2014) miR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer. Tumour Biol J Int Soc Oncodev Biol Med 35:12619–12626CrossRef
20.
Jia N, Li Q, Tao X, Wang J, Hua K, Feng W (2014) Enhancer of zeste homolog 2 is involved in the proliferation of endometrial carcinoma. Oncol Lett 8:2049–2054CrossRefPubMedPubMedCentral
21.
Eskander RN, Ji T, Huynh B, Wardeh R, Randall LM, Hoang B (2013) Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines. Int J Gynecol Cancer 23:997–1005CrossRefPubMedPubMedCentral
22.
Wu D, Jiang H, Chen S, Zhang H (2015) Inhibition of microRNA-101 attenuates hypoxia/reoxygenation induced apoptosis through induction of autophagy in H9c2 cardiomyocytes. Mol Med Rep 11:3988–3994CrossRefPubMed
23.
24.
25.
26.
Wei FZ, Cao Z, Wang X et al (2015) Epigenetic regulation of autophagy by the methyltransferase EZH2 through an MTOR-dependent pathway. Autophagy 11:2309–2322CrossRefPubMed
27.
He XP, Shao Y, Li XL et al (2012) Downregulation of miR-101 in gastric cancer correlates with cyclooxygenase-2 overexpression and tumor growth. FEBS J 279:4201–4212CrossRefPubMed
28.
Strillacci A, Valerii MC, Sansone P et al (2013) Loss of miR-101 expression promotes Wnt/beta-catenin signalling pathway activation and malignancy in colon cancer cells. J Pathol 229:379–389CrossRefPubMed
29.
Zhang J, Han C, Zhu H, Song K, Wu T (2013) miR-101 inhibits cholangiocarcinoma angiogenesis through targeting vascular endothelial growth factor (VEGF). Am J Pathol 182:1629–1639CrossRefPubMedPubMedCentral
30.
Wu X, Zhou J, Wu Z et al (2017) miR-101-3p suppresses HOX transcript antisense RNA (HOTAIR)-induced proliferation and invasion through directly targeting SRF in gastric carcinoma cells. Oncol Res 25:1383–1390CrossRefPubMed
31.
Xu Y, An Y, Wang Y et al (2013) miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep 29:2019–2024CrossRefPubMed
32.
33.
Zhou J, Roh JW, Bandyopadhyay S et al (2013) Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma. Gynecol Oncol 128:344–348CrossRefPubMed
34.
Bachmann IM, Halvorsen OJ, Collett K et al (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24:268–273CrossRefPubMed
35.
Liu TP, Lo HL, Wei LS, Hsiao HH, Yang PM (2015) S-Adenosyl-l-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells. Anticancer Drugs 26:139–147CrossRefPubMed
36.
Sun Y, Jin L, Liu JH, Sui YX, Han LL, Shen XL (2016) Interfering EZH2 expression reverses the cisplatin resistance in human ovarian cancer by inhibiting autophagy. Cancer Biother Radiophar 31:246–252CrossRef
Metadata
Title
miR-101-3p induces autophagy in endometrial carcinoma cells by targeting EZH2
Authors
Cuilan Wang
Bo Liu
Publication date
01-06-2018
Publisher
Springer Berlin Heidelberg
Published in
Archives of Gynecology and Obstetrics / Issue 6/2018
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-018-4768-7

Other articles of this Issue 6/2018

Archives of Gynecology and Obstetrics 6/2018 Go to the issue

Gynecologic Oncology

Peri-operative oral immunonutrition in malnourished ovarian cancer patients assessed by the nutritional risk screening

Review

Benign multicystic mesothelioma and peritoneal inclusion cysts: are they the same clinical and histopathological entities? A systematic review to find an evidence-based management

Gynecologic Oncology

Influence of training level on cervical cone size and resection margin status at conization: a retrospective study

General Gynecology

Comparative mid-term anatomical and functional outcomes following laparoscopic sacrocolpopexy in women under and over 65: results from a prospective study

Gynecologic Endocrinology and Reproductive Medicine

The effect of intrauterine human chorionic gonadotropin flushing on live birth rate after vitrified-warmed embryo transfer in programmed cycles: a randomized clinical trial

General Gynecology

The role of complement components C1q, MBL and C1 inhibitor in pathogenesis of endometriosis